Serum microRNA is a promising biomarker for osteogenesis imperfecta

Ziqiang Wang¹, Yanqin Lu¹, Xiumei Zhang¹, Xiuzhi Ren²,*, Yanzhou Wang³,*, Zhiliang Li⁴, Chao Xu¹, Jinxiang Han¹,**

¹ Shandong Medicinal Biotechnology Center, Key Laboratory for Biotech-Drugs Ministry of Health, Key Laboratory for Rare Disease of Shandong Province, Shandong Academy of Medical Sciences, Jinan University Shandong Academy of Medical Sciences College of Life Science and Medicine, Ji’nan, Shandong, China;
² Tianjin Hospital, Tianjin, China;
³ Shandong Provincial Hospital, Ji’nan, Shandong, China;
⁴ Wuqing People’s Hospital, Tianjin, China.

* Both authors contributed equally to the work.
** Address correspondence to:
Dr. Jinxiang Han, Shandong Academy of Medical Sciences, No. 18877 Jing-shi Road, Ji’nan, 250062, Shandong, China.
E-mail: samshjx@sina.com

1. Introduction

Osteogenesis imperfecta (OI) is a rare hereditary disease characterized by abnormality of osteoblastic proliferation and differentiation and osteoclastic activity (1). Emerging evidence has suggested that microRNAs (miRNAs) may be important mediators of ossification through binding and repressing the expression of target mRNAs whose translation products are involved in osteoblastic proliferation and differentiation and osteoclastic activity (2).

miRNA is a class of small noncoding RNAs that principally function in the spatiotemporal regulation of protein translation by binding to the 3’-untranslated region (UTR) of target mRNAs, leading to mRNA degradation or translational repression (3). Since discovered in the early 1990s, miRNAs have been shown to play important regulatory roles in a wide range of biological and pathological processes (4-6). As an existing form,
serum miRNAs are thought to be a greatly promising novel biomarker for cancers, nerve-development diseases, and some metabolic diseases with their high accuracy (sensitivity and specificity) and predictability (7). However, little attention has been devoted to the relationship between serum miRNAs expression and bone-related diseases.

To learn more about the potential relevance of serum miRNAs in bone-related diseases, we screened more than 100 bone-related miRNAs in serum samples from patients with OI and healthy controls to find OI-related miRNAs, and with bioinformation analysis, we examined whether these differential bone-related miRNAs have potential to be markers for OI diagnosis.

2. Materials and Methods

2.1. Serum collection and storage

The study protocol was approved by the Ethical Committee of Shandong Medicinal Biotechnology Center, Ji’nan, Shandong, China. Whole blood samples were collected from 22 osteogenesis imperfecta patients (age, 9.54 ± 3.65 year) and 10 healthy donors (age, 8.20 ± 0.42 year). Serum was isolated by centrifuging whole blood at 1,900 × g for 10 min at room temperature. To minimize degradation, samples were processed within 2 h. Twenty-two OI patients came from Tianjin Hospital and Shandong Provincial Hospital with patient’s informed consent, and 10 healthy controls came from volunteers in Ji’nan.

2.2. Total RNA isolation

Total RNA from serum was isolated using TRIzol LS (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. In brief, 200 μL serum was mixed with 750 μL of TRIzol LS, and then 200 μL chloroform was added, the samples were shaken vigorously for 30 sec, and allowed to stand for 5 min at room temperature. After centrifugation at 12,000 × g for 15 min at 4°C, the upper aqueous phase was transferred to a fresh tube and 600 μL isopropanol was added followed by mild mixing and incubation for 5 min at room temperature. After centrifugation at 12,000 × g for 10 min at 4°C, the upper aqueous phase was discarded and the precipitate was washed twice with 750 μL of 75% ethanol. Finally, RNA was diluted in a final volume of 15 μL RNase-free water. The RNA integrity and concentration were determined using 2% agarose gel electrophoresis and with a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

2.3. Quantification of serum miRNAs by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis

The first-strand miRNA-cDNA PCR template was generated from ~50 ng of total RNA using a miRNA first-strand cDNA synthesis kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. Then approximate 2.5 ng of cDNA was used to amplify using a miRcute miRNA qPCR detection kit (Tiangen) with a LightCycler 480 Sequence Detection System (Roche Applied Science, Mannheim, Germany). In the qRT-PCR, amplification was carried out as follows: 94°C for 2 min, 45 cycles of 94°C for 20 sec, 60°C for 20 sec, and 72°C for 20 sec. Data were generated from three independent qRT-PCR reactions and the relative quantity of miRNA expression was calculated using the comparative cycle threshold (Ct) method, in which the lowest expressed sample was used as a calibrator. Subsequently, the relative quantity was normalized using geometric averaging of selected reference genes.

2.4. Selection of reference genes

Six OI patients and 2 healthy controls with different characteristics (gender, age, and medication history) were selected as the objects for this study. In the selected 6 candidate reference genes (miR-16, miR-92a, miR-638, Let-7a, snRNAU6, and 18S rRNA), miR-16, miR-638, snRNAU6, and 18S rRNA have been regarded as common internal references (8), and miR-92a and Let-7a were two miRNAs which were stably expressed in our previous trials. Using qRT-PCR followed by geNorm software analysis, which was used to sort gene expression stability and find optimal reference gene(s) (9), the expression stability of 6 candidate reference genes was obtained and an optimal number of reference genes for normalization was determined. For verifying accuracy and universality of chose reference genes stable expression, validation was carried out by means of normFinder (10), Bestkeeper (11), and delta CT method analyses (12) and increasing sample size. Six candidate reference genes’ primer sequences were as follows: for hsa-miR-16, 5’-TAG-CAG-CAC-GTA-AAT-ATT-GGC-G-3’; for hsa-miR-92a, 5’-TAT-TGC-ACT-TGG-CGG-CCT-AAA-AA-3’; for hsa-miR-638, 5’-GGG-TGG-CCG-GCG-CCT-AAA-AA-3’; for hsa-Let-7a, 5’-TTG-AGG-TAG-TAG-GTT-GTA-TAG-TT-3’; for snRNAU6, 5’-TGC-GGG-TGC-TGG-GCT-CAG-CA-3’; for 18S rRNA, 5’-CAG-CCA-CCC-GAG-GAT-GAG-C-3’.

2.5. Screening of differential expression of bone-related miRNAs in serum of patients with OI

Through three miRNAs target genes analysis softwares, miRanda, Targetscan, and Pictar, we sorted out some miRNAs which could combine complementarily to mRNA 3’ UTR of genes functioning in osteogenesis. Together with miRNAs verified to regulate the course of bone formation, bone-related miRNAs have been chosen, and these miRNAs were quantified in serum of 8 OI patients without medication history and 8 age-matched patients.
miR-489, miR-133a, miR-145, miR-210, and miR-1297 down-expressed in serum of OI patients compared to healthy controls ($p < 0.05$) (Figure 4). In the differential expression, miRNAs, miR-29a, and miR-133a were significantly down-regulated, at 12.80-fold and 6.31-fold, respectively. Compared to the healthy control group, the quantity of miR-29a had a universal lower level in the patient group, and on the contrary, miR-26a had a universal upper level.

4. Discussion

Although real-time reverse transcriptase PCR has become the technology of choice for high-throughput and accurate expression profiling of target genes, the selection of a proper internal reference was still a festering issue. Unconditional stable expression housekeeping genes are not known to exist in nature, and will lead to large errors.

3. Results

3.1. snRNAU6, miR-92a, miR-16, and Let-7a as internal references for qRT-PCR normalization

Based on that the expression ratio of two suitable reference genes should be identical in all samples regardless of the experimental conditions, we utilized geNorm software to assess the expression stability of 6 candidate control genes and found all 6 candidate reference genes had a stable expression level in serum of 8 healthy controls and 8 patients with different characteristics ($M < 1.5$, the system default value is 1.5). The order of their expression stability is snRNAU6/miR-92a > miR-16 > Let-7a > 18S rRNA > miR-638 (Figure 1). With pairwise variation analysis, the optimal number of reference genes for normalization was determined to be 4 ($V_{4/5} = 0.133 < 0.15$, the system default value is 0.15) (Figure 2). Further validation by means of normFinder, Bestkeeper, and delta CT method analyses and increasing sample size revealed the same results (Figure 3), which revealed that snRNAU6, miR-92a, miR-16, and Let-7a could be used as an internal reference group for qRT-PCR normalization.

3.2. Differential expression of bone-related miRNAs

In the more than 100 bone-related miRNAs we have chosen with the help of software forecasts and literature reports, miR-26a, miR-30e, and miR-21 were revealed to be up-expressed and miR-34c, miR-29a, miR-29b, miR-489, miR-133a, miR-145, miR-210, and miR-1297 down-expressed in serum of OI patients compared to healthy controls ($p < 0.05$) (Figure 4). In the differential expression, miRNAs, miR-29a, and miR-133a were significantly down-regulated, at 12.80-fold and 6.31-fold, respectively. Compared to the healthy control group, the quantity of miR-29a had a universal lower level in the patient group, and on the contrary, miR-26a had a universal upper level.
with normalization based on a single reference gene (9). Therefore, we inputted geNorm software to seek out more stable genes as an internal reference group, and the qRT-PCR data was then normalized using a geometric mean of selected genes. In 4 selected reference genes, miR-16 was the most common reference for miRNAs detection in peripheral blood of various diseases, such as gastric cancer (8), prostate cancer (13), breast cancer (14), and liver cancer (15). Another gene, snRNAU6, a kind of intracellular stable expression ribosomal RNA, recently has been found to express stably in the peripheral circulation of diverse diseases, for instance, in the plasma of colorectal and oral squamous cell carcinoma, in the serum of breast cancer and in the urine of bladder cancer (15).

Most alternatively expressed bone-related miRNAs we observed have been regarded as potential biomarkers for various cancers; for instance, miR-21 was called "oncogenic miRNA", precisely because it had abnormal expression in many cancers (16-21). Although no report directly indicated that there is a close relationship between differential expression of miRNAs and bone-related diseases, these miRNAs have been verified to be involved in the course of ossification (2). While investigating the relationship between bone morphogenetic proteins (BMPs) and miRNAs in phenotypic induction in osteoprogenitors, Li Z et al. found that miR-133 functionally inhibits osteoprogenitor differentiation by attenuating Runx2 and Smad5 pathways, which synergistically contribute to bone formation (22). miR-29a has been reported to suppress expression of Dkk1, Kremen2, and sFRP2, all of which are negative regulators of Wnt signaling, which promotes osteoblast differentiation (23). In a study to determine miR-29b function, transforming growth factor beta 3 (TGFβ3) was found to inhibit osteoblast differentiation, while miR-29b was observed to promote osteoblastogenesis by directly targeting the 3' UTR sequence of TGFβ3 mRNA (24). In a similar report, miR-210 was found to enhance osteoblastogenesis by inhibiting the TGFβ/activin signaling pathway through targeting and repressing translational products of the AcvR1b gene (25).

Figure 4. Differential expression levels of eleven serum miRNAs in healthy controls and patients with OI. Data were obtained from quantitative detection of bone-related miRNAs in serum of OI patients. Closed columns, healthy controls; open columns, patients.

1. Iwamoto J, Takeda T, Ichimura S. Increased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfect type I. J Bone Miner Metab. 2002; 20:174-179.


(Received March 23, 2012; Revised April 20, 2012; Accepted April 23, 2012)